[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369027-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369027-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dienogest-use-and-the-risk-of-breast-and-gynecologic-cancers-a-nationwide-population-based-study","Dienogest use and the risk of breast and gynecologic cancers - A nationwide population-based study","","Objective: Evaluate whether dienogest exposure is associated with breast, endometrial, or tubo-ovarian cancer risk in women with endometriosis. Methods: In a nationwide retrospective cohort (Jan 2012–Dec 2023), women aged 20–49 receiving dienogest for at least 6 months were compared with an active control treated with GnRH agonists, with cohorts balanced using inverse probability of treatment weighting. Adjusted hazard ratios were estimated using Cox proportional hazards models. Results: Dienogest was not linked to increased risks of breast, endometrial, or tubo-ovarian cancer versus GnRH agonists; shorter duration showed reduced breast cancer risk. Conclusion: Findings support oncologic safety, with longer-term duration-specific studies needed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dienogest-use-and-the-risk-of-breast-and-gynecologic-cancers-a-nationwide-population-based-study/369027/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dienogest-use-and-the-risk-of-breast-and-gynecologic-cancers-a-nationwide-population-based-study/369027.png","ImageObject",300,407,{"name":42,"@type":43},"hdkawk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the objective of this nationwide study?","Question",{"text":63,"@type":64},"To evaluate whether exposure to dienogest is associated with the risk of breast, endometrial, or tubo-ovarian cancer in women with endometriosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants and comparison groups selected?",{"text":68,"@type":64},"Women aged 20–49 with endometriosis who received dienogest for at least 6 months were compared with an active control group treated with GnRH agonists, using inverse probability of treatment weighting to balance cohorts.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about cancer risk with dienogest?",{"text":72,"@type":64},"Compared with GnRH agonists, dienogest use was not associated with increased risks of breast cancer, endometrial cancer, or tubo-ovarian cancer; shorter use duration (0.5–1.5 years) was associated with reduced breast cancer risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369027,1790553745,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10. 1002/ijgo.70424  \nC L I N I CA L A RT I C L E  \nDienogest use and the risk of breast and gynecologic cancers: A nationwide population-based study  \nHoyol Jhang1 | Saerom Kim1 | Hyun-Tae Park2 | Ju-Young Shin3,4 | Seung-Ah Choe5,6   \n1Department of Public Health, Korea University, Seoul, Republic of Korea 2Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Republic of Korea 3School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea 4Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea  \n5Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea  \n6Research and Management Center for Health Risk of Particulate Matter, Korea University, Seoul, Republic of Korea  \nCorrespondence  \nSeung-Ah Choe, Department of Preventive Medicine, Korea University College of Medicine, Seoul 02841, Seoul, Republic of Korea.  \nEmail: [seungah@korea.ac.kr](seungah@korea.ac.kr)  \nFunding information  \nNational Research Foundation of Korea, Grant/Award Number:  \n2018R1D1A1B07048821 and 2022R1A2C1006364  \nAbstract  \nObjective: To evaluate whether dienogest exposure is associated with the risk of breast, endometrial, or tubo-ovarian cancer in women with endometriosis.  \nMethods: In this nationwide retrospective cohort study (January 2012 to December 2023), we used the Korean National Health Insurance Review & Assessment Service database. Women aged 20–49 years with endometriosis who received dienogest for at least 6 months were compared with an active control group treated with gonadotropin-releasing hormone (GnRH) agonists, with cohorts balanced by inverse probability of treatment weighting. Incident breast, endometrial, and tubo-ovarian cancers were ascertained, and adjusted hazard ratios (aHR) were estimated using Cox proportional hazards models.  \nResults: Among 1 887 957 women with endometriosis, 14 647 dienogest users and 181 587 GnRH agonist users met the eligibility criteria for the breast cancer cohort; sample sizes were similar for endometrial and tubo-ovarian analyses. Compared with GnRH agonists, dienogest use was not associated with increased risk of breast cancer (aHR 1.01, 95% confidence interval [CI] 0.75–1. 37), endometrial cancer (aHR 0. 84, 95% CI 0.40–1.77), or tubo-ovarian cancer (aHR 0.92, 95% CI 0.30–2. 80) . Use of dienogest for 0.5–1. 5 years was associated with a reduced breast cancer risk (aHR 0.72, 95% CI 0.53–0.99), whereas associations for longer durations were inconsistent. Conclusion: Dienogest use in women with endometriosis was not associated with higher or lower risks of breast, endometrial, or tubo-ovarian cancer compared with GnRH agonists, supporting its oncologic safety. Further longer-term studies are warranted to clarify duration-specific effects.  \nK E Y WO R D S  \nbreast, cancer, Dienogest, endometriosis, endometrium, ovary, safety  \n1 | INTRODUCTION  \nEndometriosis has a high recurrence rate even after appropriate surgical intervention, making long-term pharmacotherapy—focused  \non pain reduction and recurrence prevention—the cornerstone of management. It is therefore essential to understand clearly the correct use and potential adverse effects of each therapeutic agent. Traditional pharmacologic options comprise gonadotropin-releasing  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s) . International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.  \n1124  \nJHANG et al.  \nhormone (GnRH) agonists, danazol, and combined oral contraceptives, but their adverse-effe","cbCaii5r7iaOv5oy","https://ap.wps.com/l/cbCaii5r7iaOv5oy","pdf",838087,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Background on endometriosis and treatment\n## Dienogest pharmacology and approval history\n## Cancer risk context and mechanisms","[{\"question\":\"What was the objective of this nationwide study?\",\"answer\":\"To evaluate whether exposure to dienogest is associated with the risk of breast, endometrial, or tubo-ovarian cancer in women with endometriosis.\"},{\"question\":\"How were participants and comparison groups selected?\",\"answer\":\"Women aged 20–49 with endometriosis who received dienogest for at least 6 months were compared with an active control group treated with GnRH agonists, using inverse probability of treatment weighting to balance cohorts.\"},{\"question\":\"What did the study find about cancer risk with dienogest?\",\"answer\":\"Compared with GnRH agonists, dienogest use was not associated with increased risks of breast cancer, endometrial cancer, or tubo-ovarian cancer; shorter use duration (0.5–1.5 years) was associated with reduced breast cancer risk.\"}]","Dienogest use and the risk of breast and gynecologic cancers - A nationwide population-based study | PDF",1790180232,18,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e43ddc5812ed8cebc027efc19bbd48fe.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b87363a9e5ed00bb6ef24f9038989c7a.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d7f83fe733df1b2949cb84075efb5b9.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2a9a461c406252b1e5c87903d5a3d41.webp",980,1287]